Back to top
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
medical: Archive
Philips (PHG) Receives FDA Warning Letter Regarding CT Systems
by Zacks Equity Research
Philips (PHG) receives a warning letter from the FDA in respect of a manufacturing plant in China regarding faults in the manufacturing of CT systems.
ECLPositive Net Change PHGPositive Net Change BDXPositive Net Change IDXXPositive Net Change
medical medical-devices
Factors Setting the Tone For Lantheus' (LNTH) Q1 Earnings
by Zacks Equity Research
Lantheus' (LNTH) first-quarter results are likely to reflect solid top-line performance on the back of robust product adoption.
CAHNegative Net Change EWNegative Net Change LNTHPositive Net Change SIBNPositive Net Change
medical medical-devices
Factors Setting the Tone for Ecolab's (ECL) Q1 Earnings
by Zacks Equity Research
Ecolab's (ECL) first-quarter results are likely to reflect continued segmental strength.
ECLPositive Net Change UHSPositive Net Change THCNegative Net Change BPMCPositive Net Change
earnings medical medical-devices
Integer Holdings (ITGR) Q1 Earnings Top Estimates, Margins Up
by Zacks Equity Research
Integer Holdings' (ITGR) first-quarter results reflect robust Medical Sales, along with strength in all the product lines.
LHPositive Net Change ALGNNegative Net Change RMDPositive Net Change ITGRNegative Net Change
earnings medical medical-devices
Ocugen (OCGN) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Ocugen (OCGN) is expected to provide updates regarding the developmental program of its lead candidate, OCU400, for two rare retinal diseases in the first-quarter earnings release.
ALNYNegative Net Change SRPTPositive Net Change ARGXPositive Net Change OCGNPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Centene (CNC) Q1 Earnings Beat on Premiums, '24 EPS View Hiked
by Zacks Equity Research
Centene's (CNC) Q1 results reflect strength in the Commercial business line. Management currently expects adjusted EPS to be greater than $6.80 for 2024.
UHSPositive Net Change HUMNegative Net Change MOHNegative Net Change CNCNegative Net Change
earnings medical
AbbVie (ABBV) Beats on Q1 Earnings & Sales, Ups '24 EPS View
by Zacks Equity Research
AbbVie's (ABBV) first-quarter earnings and sales beat estimates. Management hikes the EPS guidance on the back of encouraging Skyrizi product sales.
RHHBYPositive Net Change JNJNegative Net Change ABBVNegative Net Change GMABPositive Net Change
biotechs earnings medical pharmaceuticals
3 Medical Products Stocks Set to Beat This Earnings Season
by Urmimala Biswas
Here are three stocks, TXG, CAH and HOLX, which are expected to beat earnings estimates in the ongoing reporting cycle.
BSXNegative Net Change LHPositive Net Change CAHNegative Net Change HOLXPositive Net Change TXGPositive Net Change
earnings medical medical-devices
Sage Therapeutics (SAGE) Q1 Earnings Miss, Sales Beat Estimates
by Zacks Equity Research
Sage Therapeutics' (SAGE) first-quarter 2024 results are mixed as earnings miss estimates, but sales beat the mark. The newly-launched depression drug Zurzuvae drives the company's top line.
BIIBPositive Net Change LGNDPositive Net Change ANIPPositive Net Change SAGEPositive Net Change
biotechs medical pharmaceuticals
Edwards Lifesciences (EW) Q1 Earnings Top, 2024 Sales View Up
by Zacks Equity Research
Strong performance of SAPIEN 3 Ultra RESILIA platform and sustainable TAVR growth drives Edwards Lifesciences (EW) Q1 revenues.
EWNegative Net Change EXASPositive Net Change INSPPositive Net Change TMDXPositive Net Change
earnings medical medical-devices
Gilead (GILD) Q1 Loss Narrower Than Expected, Sales Beat
by Zacks Equity Research
Gilead (GILD) reports narrower-than-expected loss in the first quarter. Its sales beat estimates on higher HIV, Oncology and Liver Disease sales.
GILDPositive Net Change ANIPPositive Net Change ADMAPositive Net Change XLOPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Should Lifeward (LFWD) be in Your Portfolio Ahead of Q1 Earnings?
by Moumi Mondal
Lifeward's (LFWD) first-quarter 2024 results are expected to reflect the benefits of several milestone achievements from last year.
INSPPositive Net Change TMDXPositive Net Change HITINo Net Change LFWDPositive Net Change
earnings medical medical-devices
Fusion (FUSN) to Report Q1 Earnings: Here's What to Expect
by Zacks Equity Research
Fusion (FUSN) is expected to provide updates regarding the developmental program of its lead candidate, FPI-2265, for prostate cancer in the first-quarter earnings release.
AZNPositive Net Change MRKPositive Net Change SRPTPositive Net Change FUSNPositive Net Change
biotechnology biotechs earnings medical oncology-screening pharmaceuticals
ResMed (RMD) Q3 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
ResMed's (RMD) fiscal 2024 third-quarter performance reflects another strong period of execution across the entire business, resulting in impressive top and bottom-line growth.
RMDPositive Net Change HCANegative Net Change INSPPositive Net Change TMDXPositive Net Change
earnings medical medical-devices
The Zacks Analyst Blog Highlights Cigna Group, HCA Healthcare, Avantor and Tenet Healthcare
by Zacks Equity Research
Cigna Group, HCA Healthcare, Avantor and Tenet Healthcare are part of the Zacks top Analyst Blog.
CINegative Net Change THCNegative Net Change HCANegative Net Change AVTRNegative Net Change
medical
Zacks Industry Outlook Highlights Elevance Health Medpace and Doximity
by Zacks Equity Research
Elevance Health, Medpace and Doximity are part of the Zacks Industry Outlook article.
MEDPPositive Net Change DOCSPositive Net Change ELVNegative Net Change
medical
Cencora (COR) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Cencora's (COR) second-quarter fiscal 2024 results are likely to reflect solid performance in the U.S. Healthcare Solutions segment.
CAHNegative Net Change CORPositive Net Change NVCRPositive Net Change SIBNPositive Net Change
medical medical-devices
DexCom (DXCM) Q1 Earnings Beat, Strong CGM Demand Continues
by Zacks Equity Research
DexCom's (DXCM) first-quarter 2024 results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.
ECLPositive Net Change BDXPositive Net Change DXCMNegative Net Change IDXXPositive Net Change
earnings medical medical-devices
Biotech Stock Roundup: BIIB, BMY's Q1 Earnings, INCY's Acquisition & Updates from VRTX
by Zacks Equity Research
Biogen (BIIB) and Bristol Myers (BMY) are in focus following Q1 earnings announcement.
BIIBPositive Net Change BMYPositive Net Change VRTXNegative Net Change INCYPositive Net Change
biotechnology biotechs medical pharmaceuticals
Molina Healthcare (MOH) Q1 Earnings Beat on Growing Membership
by Zacks Equity Research
Molina Healthcare's (MOH) Q1 results reflect strong premium revenue growth. It continues to estimate adjusted EPS at a minimum of $23.50 for 2024.
UNHPositive Net Change HUMNegative Net Change MOHNegative Net Change ELVNegative Net Change
earnings medical
AstraZeneca (AZN) Q1 Earnings & Sales Beat Estimates, Stock Up
by Zacks Equity Research
AstraZeneca (AZN) beats first-quarter estimates for earnings and sales, driven by increased demand for its key oncology and rare disease drugs.
SNYNegative Net Change AZNPositive Net Change MRKPositive Net Change AMGNPositive Net Change
biotechs medical pharmaceuticals vaccines
ICON (ICLR) Q1 Earnings Surpass Estimates, Margins Expand
by Zacks Equity Research
ICON's (ICLR) first-quarter 2024 performance is driven by its efficient service delivery and strong cost control.
ICUIPositive Net Change ICLRPositive Net Change EXASPositive Net Change INSPPositive Net Change
earnings medical medical-devices
Align Technology (ALGN) Q1 Earnings Top, 2024 Sales View Up
by Zacks Equity Research
Align Technology's (ALGN) first quarter 2024 revenue growth was up across all regions and was driven by strong Clear Aligner volumes, primarily in the Asia Pacific region.
ALGNNegative Net Change ICUIPositive Net Change EXASPositive Net Change INSPPositive Net Change
earnings medical medical-devices
Is a Surprise Coming for Avantor (AVTR) This Earnings Season?
by Zacks Equity Research
Avantor (AVTR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
AVTRNegative Net Change
medical
Revvity's (RVTY) New Launch to Boost Tuberculosis Testing
by Zacks Equity Research
Revvity's (RVTY) latest offering is likely to provide a new and improved workflow to lower hands-on time and enable increased lab productivity.
ECLPositive Net Change BDXPositive Net Change IDXXPositive Net Change RVTYNegative Net Change
medical medical-devices